Bispecific antibody

Buoyed by bumper earnings, the biotech has announced a share placement to raise HK$1.17 billion to invest in developing its portfolio of anti-cancer drugs.

Akeso marks profit milestone with swift rights issue

Buoyed by bumper earnings, the biotech has announced a share placement to raise HK$1.17 billion to invest in developing its portfolio of anti-cancer drugs Key Takeaways: Akeso swung to an…
9926.HK

Recent Articles

RELATED ARTICLES

  1. BeiGene
    BeiGene heads for profit milestone after hemorrhaging cash
    6160.HK ONC.US 688235.SHG
  2. Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
    1952.HK
  3. Cancer drug maker Genfleet joins Hong Kong IPO influx
  4. Everest Medicines drives growth with AI-powered mRNA pipeline
    1952.HK
  5. A blockbuster cancer drug? TYK’s claims go under the microscope
    2410.HK
  6. Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
    1952.HK
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva